Clinical Trial Search

Phase 3 N=93 Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)

UC (Urothelial Cancer)

Primary: Objective Response Rate (ORR) With Pembrolizumab + Epacadostat Versus Pembrolizumab + Placebo — 31.8; 24.5 percentage of participants

Incyte Corporation Results Aug 2019 50.0% serious AE View details

Phase 3 N=699 Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.

Malaria · Malaria Vaccines

Primary: Anti-Circumsporozoite (Anti-CS) Antibody Concentrations, One Month Post Dose 3 of SB257049 (Primary Analysis) — 452.87; 422.49 EU/mL

GlaxoSmithKline Results Aug 2019 27.0% serious AE View details

Phase 3 N=219 A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.

Generalized Tonic Clonic Seizures

Primary: Log-transformed (Log) 28-day Seizure Rate for All Primary Generalized Tonic-Clonic (PGTC) Seizures During 12-Week Double-Blind Treatment Phase — 1.17; 1.13; 1.14 Seizure…

Pfizer's Upjohn has merged with Mylan to form… Results Aug 2019 3.2% serious AE View details

Phase 3 N=43 Can Pregabalin Reduce the Frequency and Severity of Dry Eye Symptoms After Laser-assisted in Situ Keratomileusis?

Dry Eye

Primary: Severity of Dry Eye Symptoms as Assessed by the Dry Eye Questionnaire - 5 (DEQ5) — 6.6; 4.5 score on a scale

University of Miami Results Aug 2019 0.0% serious AE View details

Phase 3 N=311 Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination

Infections, Meningococcal

Primary: Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers Greater Than or Equal to (>=) 1:8 and >=1:128 For Each…

Pfizer Results Aug 2019 0.0% serious AE View details

Phase 3 N=203 Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia

Primary: Percentage of Time With a Platelet Response During the First 6 Months of Treatment — 50.00 percentage of time

Amgen Results Aug 2019 29.6% serious AE View details

Phase 3 N=577 Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes

Diabetes · Diabetes Mellitus, Type 2

Primary: Change in HbA1c — -1.7; -1.1 Percentage of glycosylated haemoglobin — p=<0.0001

Novo Nordisk A/S Results Aug 2019 6.8% serious AE View details

Phase 3 N=33 Comparison of Indigo Naturalis Oil Extract and Calcipotriol Solution in Treating Psoriasis

Nail Psoriasis

Primary: Change From Baseline in Single-handed Nail Psoriasis Severity Index (shNAPSI) at 24 Weeks — 27.2; 27.4; 14.4; 20.4 units on a scale

Yin-ku Lin Results Aug 2019 0.0% serious AE View details

Phase 3 N=204 Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin

Lung Cancer (NSCLC)

Primary: Overall Survival (OS) of All Randomized Participants Who Received at Least One Dose of Blinded Study Therapy — NA; NA months

Bristol-Myers Squibb Results Aug 2019 35.8% serious AE View details

Phase 3 N=1,022 Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)

Major Depressive Disorder

Primary: Montgomery-Asberg Depression Rating Scale (MADRS) at Baseline in the Double-Blind Period — 25.2; 25.4 score on a scale

Forest Laboratories Results Aug 2019 0.8% serious AE View details

Phase 3 N=306 Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)

Hyperlipoproteinemia Type II · Hypercholesterolemia, Familial

Primary: Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) - Treatment Phase — -36.0; 3.7 Percent Change — p=<0.001

Merck Sharp & Dohme LLC Results Aug 2019 5.5% serious AE View details

Phase 3 N=1,254 An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine

Migraine, With or Without Aura

Primary: Percentage of Participants With at Least 1 Treatment Emergent Adverse Event — 65; 66.3; 72.6 Percentage of Participants

Allergan Results Aug 2019 3.1% serious AE View details

Phase 3 N=1,890 Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine

Migraine

Primary: Number of Participants With Adverse Events (AEs) — 365; 456; 365; 426 Participants

Teva Branded Pharmaceutical Products R&D, Inc. Results Aug 2019 6.1% serious AE View details

Phase 3 N=84 Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma

UC (Urothelial Cancer)

Primary: Objective Response Rate (ORR) With Pembrolizumab + Epacadostat Versus Pembrolizumab + Placebo — 21.4; 9.5 percentage of participants

Incyte Corporation Results Aug 2019 45.8% serious AE View details

Phase 3 N=6,097 S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.

Breast Cancer

Primary: Disease-free Survival — 88; 88; 87 percentage of analyzed participants — p=0.49

SWOG Cancer Research Network Results Aug 2019 6.0% serious AE View details